Relevant bibliographies by topics / Lymphomas - Molecular aspects

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters

Academic literature on the topic 'Lymphomas - Molecular aspects'

Author: Grafiati
Published: 4 June 2021
Last updated: 16 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Lymphomas - Molecular aspects.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Lymphomas - Molecular aspects"

1

Owens, Scott R., and Lauren B. Smith. "Molecular Aspects of H. pylori-Related MALT Lymphoma." Pathology Research International 2011 (January 24, 2011): 1–8. http://dx.doi.org/10.4061/2011/193149.

Full text
Abstract:
Helicobacter pylori-related extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue is a paradigm for malignancy arising in an inflammatory background. While the diagnosis of H. pylori gastritis is often straightforward, distinction between severe gastritis and early lymphoma can be difficult and requires careful assessment of clinical findings in addition to histological features and immunohistochemical results. A number of cytogenetic abnormalities have been discovered in H. pylori-related lymphomas and several have clinical importance, related to the responsiveness of lymphoma to H. pylori eradication therapy, but routine molecular studies are not widely utilized. While molecular methods may be used in equivocal cases, a trial of conservative therapy is warranted given the propensity for these lymphomas to regress with eradication of the organism. Once therapy is initiated, care must be taken to avoid a premature assignment of disease refractoriness because complete response can take several months to more than a year. Cases truly refractory to H. pylori eradication therapy may be treated with adjuvant chemoradiation with a high response rate.
APA, Harvard, Vancouver, ISO, and other styles
2

Barth, Thomas F. E., Martin Bentz, Hartmut Döhner, and Peter Möller. "Molecular Aspects of B-Cell Lymphomas of the Gastrointestinal Tract." Clinical Lymphoma 2, no. 1 (2001): 57–64. http://dx.doi.org/10.3816/clm.2001.n.012.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Burg, Günter, Werner Kempf, Antonio Cozzio, et al. "WHO/EORTC classification of cutaneous lymphomas 2005: histological and molecular aspects." Journal of Cutaneous Pathology 32, no. 10 (2005): 647–74. http://dx.doi.org/10.1111/j.0303-6987.2005.00495.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Richards, Kristy L., Alison Motsinger-Reif, Hsiao-Wei Chen, et al. "Characterizing Canine Lymphoma As a Potential Large Animal Model of Human Diffuse Large B-Cell Lymphoma." Blood 118, no. 21 (2011): 5193. http://dx.doi.org/10.1182/blood.v118.21.5193.5193.

Full text
Abstract:
Abstract Abstract 5193 Diffuse large B-cell lymphoma (DLBCL) affects ∼25,000 people in the U.S. each year, and fewer than half of them are cured with standard therapy. DLBCL can be divided into two subtypes by gene expression profiling, germinal center B-cell (GCB) type and activated B-cell (ABC) type. ABC-type DLBCL patients have significantly poorer outcomes. To improve therapeutic options, better animal models that accurately mimic human DLBCL (hDLBCL) are needed. Canine DLBCL is one of the most common cancers in veterinary oncology. Similar to human DLBCL patients, dogs with lymphoma are treated with both CHOP-like regimens and autologous stem cell transplants. Morphologically, canine lymphomas are similar to hDLBCL, with shared histologic markers, such as CD20 and PAX5. With recent technologies based on knowledge of the canine genome sequence, it is now possible to evaluate dogs as a potential large-animal model for hDLBCL. We evaluated 58 canine B-cell lymphomas by generating comprehensive gene expression profiles and comparing them to previously published hDLBCL expression profiles. Canine B-cell lymphoma expression profiles were similar in some ways to hDLBCLs. For instance, increased expression of NF-kB pathway genes was noted in a subset of lymphomas, mirroring NF-kB pathway activation in human ABC-type DLBCL. Furthermore, immunoglobulin heavy chain (IGH) mutation status, which is correlated with ABC/GCB cell of origin in hDLBCL, separated canine DLBCL into two groups with statistically different progression-free and overall survival times. However, canine DLBCL differed from hDLBCL in other aspects, including rare immunohistochemical positivity for BCL6 and MUM1/IRF4. Collectively, these results define aspects of canine B-cell lymphomas that resemble hDLBCL, identifying molecular similarities that could allow dogs to be used as a representative model of hDLBCL. Further comparative studies, including therapeutic trials, could potentially improve outcomes in both species. Disclosures: No relevant conflicts of interest to declare.
APA, Harvard, Vancouver, ISO, and other styles
5

Lachar, Whitney A., Imran Shahab, and A. Joe Saad. "Accuracy and Cost-Effectiveness of Core Needle Biopsy in the Evaluation of Suspected Lymphoma: A Study of 101 Cases." Archives of Pathology & Laboratory Medicine 131, no. 7 (2007): 1033–39. http://dx.doi.org/10.5858/2007-131-1033-aacocn.

Full text
Abstract:
Abstract Context.—Lymphomas have traditionally been diagnosed on excisional biopsies of lymph nodes in order to evaluate tissue architecture and cytomorphology. Recent lymphoma classification schemes emphasize immunophenotypic, genetic, and molecular aspects in addition to morphology as diagnostic features. Core needle biopsies are increasingly being used to obtain tissue for diagnosis in patients with lymphadenopathy and a clinical suspicion of lymphoma. These procedures are rapid, minimally invasive, well tolerated, and may provide some architectural framework (unlike fine-needle aspirations), as well as material for ancillary studies. Objective.—To explore the accuracy, utility, and cost-effectiveness of this technique. Design.—Core needle biopsies of 101 consecutive patients from 2 large community hospitals who were suspected of having primary or recurrent lymphomas were retrospectively reviewed. All patients had hematoxylin-eosin–stained sections of needle cores. Specimens morphologically suspicious for lymphoma were subjected to ancillary studies, including immunohistochemistry, flow cytometry, and/or molecular studies. Core needle biopsy diagnoses were correlated with subsequent excisional biopsies, if performed. Results.—Core needle biopsies established a definitive pathologic diagnosis for the vast majority of cases. A diagnosis was considered sufficient to begin treatment for primary and recurrent lymphomas in most cases. Compared with an open biopsy, there is a cost savings of greater than 75%. Conclusion.—The accuracy of this technique, along with the cost savings and decreased morbidity, suggest that this method may be used safely and reliably as a first-line diagnostic technique.
APA, Harvard, Vancouver, ISO, and other styles
6

Nguyen, Lynh, Peter Papenhausen, and Haipeng Shao. "The Role of c-MYC in B-Cell Lymphomas: Diagnostic and Molecular Aspects." Genes 8, no. 4 (2017): 116. http://dx.doi.org/10.3390/genes8040116.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Braziel, Rita M., Margaret A. Shipp, Andrew L. Feldman, et al. "Molecular Diagnostics." Hematology 2003, no. 1 (2003): 279–93. http://dx.doi.org/10.1182/asheducation-2003.1.279.

Full text
Abstract:
Abstract It is increasingly evident that molecular diagnostics, that is, the use of diagnostic testing to understand the molecular mechanisms of an individual patient’s disease, will be pivotal in the delivery of safe and effective therapy for many diseases in the future. A huge body of new information on the genetic, genomic and proteomic profiles of different hematopoietic diseases is accumulating. This chapter focuses on new technologies and advancements in understanding the molecular basis of hematologic disorders, providing an overview of new information and its significance to patient care. In Section I, Dr. Braziel discusses the impact of new genetic information and research technologies on the actual practice of diagnostic molecular hematopathology. Recent and projected changes in methodologies and analytical strategies used by clinical molecular diagnostics laboratories for the evaluation of hematologic disorders will be discussed, and some of the challenges to clinical implementation of new molecular information and techniques will be highlighted. In Section II, Dr. Shipp provides an update on current scientific knowledge in the genomic profiling of malignant lymphomas, and describes some of the technical aspects of gene expression profiling. Analysis methods and the actual and potential clinical and therapeutic applications of information obtained from genomic profiling of malignant lymphomas are discussed. In Section III, Dr. Liotta presents an update on proteomic analysis, a new and very active area of research in hematopoietic malignancies. He describes new technologies for rapid identification of different important proteins and protein networks, and the potential therapeutic and prognostic value of the elucidation of these proteins and protein pathways in the clinical care of patients with malignant lymphomas.
APA, Harvard, Vancouver, ISO, and other styles
8

Christie, Amanda L., Samuel Y. Ng, Raphael Koch, et al. "T-Cell Lymphoma Patient-Derived Xenografts and Newly Developed Cell Lines Recapitulate Aspects of Disease Biology and Represent Novel Tools for Preclinical Drug Development." Blood 128, no. 22 (2016): 3015. http://dx.doi.org/10.1182/blood.v128.22.3015.3015.

Full text
Abstract:
Abstract Lymphomas represent nearly 70 distinct diseases with unique clinical presentations, therapeutic responses and underlying biology. There is a pressing shortage of publically available cell line and in vivo models of nearly all of these diseases; T-cell lymphoma models are particularly under-represented compared to B-cell lymphomas, which has severely hampered efforts to understand and target their biology. The majority ofin vivo models of T-cell lymphomas are genetically-engineered mouse models, which often don't faithfully recapitulate human disease. To address this issue, we have established a repository of patient-derived xenografts (PDX) of lymphomas by engrafting human tumors into immunodeficient NOD/Scid/IL2rgnull mice with or without an MHC Class 1 deficiency (to prevent graft versus host disease). Blood and bone marrow specimens involved with tumor were injected by tail vein injection. Lymph node and extranodal biopsy specimens were implanted under the renal capsule as a 1x1x2mm tumor seed, which maintains the in situ microarchitecture. A description of T-cell lymphoma PDXs is included in the Table. PDXs have been extensively characterized by immunohistochemistry (IHC), flow cytometry, transcriptome sequencing and targeted DNA sequencing. These studies have demonstrated retention of key architectural, cellular, and molecular features of the primary tumors. Flow cytometric analysis of patient tumors and their respective xenografts revealed highly concordant patterns of surface marker expression. IHC of murine tissues confirmed retention of tumor immunophenotypes, architecture, and even tissue tropism in the PDXs. For example, blood from a patient with Sézary Syndrome manifested in the skin of recipient mice when injected into the lateral tail vein. A breast implant-associated ALK-negative anaplastic large cell lymphoma (ALCL) implanted under the renal capsule metastasized to the liver and spleen while uniformly retaining CD30 positivity. A peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) specimen implanted under the renal capsule engrafted in the spleen, with the notable admixture of nonmalignant T cells and scattered EBV-positive B cells in first passage. T-cell receptor gene rearrangement PCR performed on this PTCL-NOS demonstrated an identical rearrangement pattern in the primary tumor and the PDX. An angioimmunoblastic T-cell lymphoma (AITL) specimen engrafted in spleen, lymph node and bone marrow within 6 weeks and serially transplanted through three generations in an orthotopic manner while maintaining a CD3+CD4+PD1+CD30partial immunophenotype. The genetic characterization of the PDX models using a targeted DNA sequencing approach showed a mutational profile that clearly matched primary T-cell lymphoma samples and significantly expands the current repertoire of available pre-clinical models. For example, a PDX model of AITL showed mutations of TET2 and ARID1B; a model of an ALK-negative ALCL harbored mutations of STAT3 and STAT5. This massively extends the spectrum of clinically representative model systems that can be used to explore novel therapeutic strategies for T-cell lymphomas. Several early-passage PDXs have been used to generate T-cell lymphoma cells lines, including three cell lines from AITL PDX models. One of these AITL cell lines has proliferated through 30 passages and was validated by immunophenotype and molecular confirmation of bi-allelic TET2 mutations with loss of 6q, 7q, and 10q confirmed using Sanger and TruSeq Custom Amplicon Sequencings. To our knowledge, there have been no reports of an AITL cell line in the literature. Additional peripheral T-cell lymphoma cell lines are currently under development. These lymphomas, along with a spectrum of PDXs of other hematologic malignancies, are available to collaborators through the online portal PRoXe (Public Repository of Xenografts) at www.proxe.org. These models represent a unique opportunity to interrogate biology and perform preclinical studies with in vivo models. Table 1 Table 1. Disclosures Jacobson: Kite: Membership on an entity's Board of Directors or advisory committees. Armand:Pfizer: Research Funding; Sequenta Inc: Research Funding; Merck: Consultancy, Research Funding; Roche: Research Funding; Infinity Pharmaceuticals: Consultancy; Bristol-Myers Squibb: Consultancy, Research Funding. Shipp:Bristol-Myers Squibb: Consultancy, Research Funding; Cell Signaling: Honoraria; Merck, Gilead, Takeda: Other: Scientific Advisory Board; Bayer: Research Funding. Fisher:Pharmacyclics: Consultancy. Weinstock:Novartis: Consultancy, Research Funding.
APA, Harvard, Vancouver, ISO, and other styles
9

Barroca, Helena, and Cristina Marques. "A Basic Approach to Lymph Node and Flow Cytometry Fine-Needle Cytology." Acta Cytologica 60, no. 4 (2016): 284–301. http://dx.doi.org/10.1159/000448679.

Full text
Abstract:
According to the World Health Organization (WHO), the new classification of lymphomas is mainly based on morphological, immunophenotypical, and molecular criteria. Consequently, this new approach has led from the substantial role that architecture played in the past to a secondary panel highlighting the role of fine-needle biopsy (FNB). Applied together with other ancillary techniques, such as flow cytometry (FC), FNB is a potential tool for the diagnosis of lymphomas, and enlarged lymph nodes represent an excellent target for the implementation of this technique. Despite the difficulties inherent in this technology, which might pose problems in differential diagnosis, in the majority of cases this joint work allows an accurate diagnosis of malignancy and even correct subcharacterization in routine lymphomas. Additionally, in selected cases, other molecular techniques like FISH and PCR can also be performed on FNB specimens, helping in the characterization and diagnosis of lymphomas. In this review, we discuss the basic aspects of the combination of FNB cytology and FC in the diagnosis and subclassification of lymphomas. The preanalytical phase is extensively discussed. The advantages, disadvantages, and technical limitations of this joint work are addressed in general and in terms of the accurate subclassification of lymphomas.
APA, Harvard, Vancouver, ISO, and other styles
10

Ikeda, Tomoka, Yuka Gion, Yoshito Nishimura, Midori Filiz Nishimura, Tadashi Yoshino, and Yasuharu Sato. "Epstein–Barr Virus-Positive Mucocutaneous Ulcer: A Unique and Curious Disease Entity." International Journal of Molecular Sciences 22, no. 3 (2021): 1053. http://dx.doi.org/10.3390/ijms22031053.

Full text
Abstract:
Epstein–Barr virus (EBV)-positive mucocutaneous ulcer (EBVMCU) was first described as a lymphoproliferative disorder in 2010. EBVMCU is a unifocal mucosal or cutaneous ulcer that often occurs after local trauma in patients with immunosuppression; the patients generally have a good prognosis. It is histologically characterized by proliferating EBV-positive atypical B cells accompanied by ulcers. On the basis of conventional pathologic criteria, EBVMCU may be misdiagnosed as EBV-positive diffuse large B-cell lymphoma or other lymphomas. However, its prognosis differs from that of EBV-associated lymphomas, in that patients with EBVMCU frequently show spontaneous regression or complete remission without chemotherapy. Therefore, EBVMCU is now recognized as a low-grade malignancy or a pseudo-malignant lesion. Avoiding unnecessary chemotherapy by distinguishing EBVMCU from other EBV-associated lymphomas will reduce the burden and unnecessary harm on patients. On the basis of these facts, EBVMCU was first described as a new clinicopathological entity by the World Health Organization in 2017. In this review, we discuss the clinicopathological characteristics of previously reported EBVMCU cases, while focusing on up-to-date clinical, pathological, and genetic aspects.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Lymphomas - Molecular aspects"

1

陳遠雯 and Yun-wen Wendy Chen. "Molecular genetics of gastric non-Hodgkin's B-cell lymphomas." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2003. http://hub.hku.hk/bib/B3124404X.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Ma, Huan, and 马欢. "Molecular analysis of ocular adnexal lymphomas in the search for potential biomarkers." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2011. http://hub.hku.hk/bib/B46921655.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

徐維勝 and Wei-sheng Xu. "Gastric lymphoma of MALT type: the etiologic factors and the molecular basis of pathogenesis." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 1998. http://hub.hku.hk/bib/B31239572.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Chan, Ka-kui, and 陳家駒. "Molecular mechanisms of IL-2 mediated BCL10 nuclear localization and the therapeutic role of an anti-CD25 antibody in nasal NK-celllymphoma." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2009. http://hub.hku.hk/bib/B4218244X.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Au, Wing-yan, and 區永仁. "Pathogenesis and progression of malignant B cell neoplasms." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2005. http://hub.hku.hk/bib/B45007676.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Berglund, Mattias. "Molecular Characterization of Diffuse Large B-cell Lymphoma and Aspects of Transformation." Doctoral thesis, Uppsala : Acta Universitatis Upsaliensis : Univ.-bibl. [distributör], 2004. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-4266.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Yip, Bon-ham, and 葉邦瀚. "Immunoglobulin gene translocations in gastric lymphoma." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2006. http://hub.hku.hk/bib/B37345321.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Vignaux-Boraud, Delphine. "Intérêt de l'étude des cellules de Sézary : étude parallèle en biologie moléculaire par PCR des clones T sanguins et cutanés." Bordeaux 2, 2000. http://www.theses.fr/2000BOR23099.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Bal, Shibani. "Cytogenetics and molecular aspects of nonHodgkin's lymphoma." 1990. http://hdl.handle.net/1993/17012.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Lymphomas - Molecular aspects"

1

F, Grignani, Martelli M. F, and Mason D. Y, eds. Genotypic, phenotypic, and functional aspects of haematopoiesis. Raven Press, 1987.

APA, Harvard, Vancouver, ISO, and other styles
2

Kaspers, G. J. L., 1963-, Pieters R, and International Symposium on Drug Resistance in Leukemia and Lymphoma (3rd : 1998 : Amsterdam, Netherlands), eds. Drug resistance in leukemia and lymphoma III. Kluwer Academic/Plenum Press, 1999.

APA, Harvard, Vancouver, ISO, and other styles
3

Kaspers, G. J. L., 1963-, Pieters R, Veerman A. J. P, and International Symposium on Drug Resistance in Leukemia and Lymphoma (3rd : 1998 : Amsterdam, Netherlands), eds. Drug resistance in leukemia and lymphoma III. Kluwer Academic/Plenum Publishers, 1999.

APA, Harvard, Vancouver, ISO, and other styles
4

G.J.L. Kaspers (Editor), R. Pieters (Editor), and A.J.P. Veerman (Editor), eds. Drug Resistance in Leukemia and Lymphoma III (Advances in Experimental Medicine and Biology). Springer, 1999.

APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Lymphomas - Molecular aspects"

1

de Leval, Laurence, Francine Foss, and Philippe Gaulard. "Molecular and Clinical Aspects of Angioimmunoblastic T-Cell Lymphoma." In T-Cell Lymphomas. Humana Press, 2012. http://dx.doi.org/10.1007/978-1-62703-170-7_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Juszczyński, Przemysław, and Krzysztof Warzocha. "Molecular Pathogenesis of Aggressive B-cell Lymphomas." In Molecular Aspects of Hematologic Malignancies. Springer Berlin Heidelberg, 2012. http://dx.doi.org/10.1007/978-3-642-29467-9_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Wislez, Marie, Raphael Borie, Catherine Thieblemont, Marie-France Carette, Martine Antoine, and Jacques Cadranel. "Pulmonary MALT Lymphoma: Clinical, Molecular and Therapeutic Aspects." In Pulmonary Involvement in Patients with Hematological Malignancies. Springer Berlin Heidelberg, 2010. http://dx.doi.org/10.1007/978-3-642-15742-4_40.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

"Cellular and molecular aspects." In Fast Facts: Lymphoma. S. Karger AG, 2018. http://dx.doi.org/10.1159/000494518.

Full text
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography